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Perspective: Recurrent PAF post-ablation most often is asso-
ciated with recovery of PV conduction. Note that the 67%
efficacy in this study was based only on recurrences of symp-
tomatic PAF. If asymptomatic PAF also was included,
efficacy most likely would have been lower. This, and the
large number of laser applications needed to achieve acute
PV isolation, suggests that the ELAS may need refinement
to more effectively achieve permanent PV isolation.  
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Management of Moderate Functional Mitral
Regurgitation at the Time of Aortic Valve
Replacement: Is Concomitant Mitral Valve Repair
Necessary
Wan CK, Suri RM, Li Z, et al.
J Thorac Cardiovasc Surg 2009;137:635–640.
Study Design: What is the natural history of moderate func-
tional mitral regurgitation (MR) at the time of aortic valve
replacement (AVR)?
Methods: Of the 5,855 patients undergoing AVR or aortic root
replacement (1993-2006), 686 had at least moderate concomi-
tant MR. After exclusions such as those with concomitant
coronary bypass grafting, coronary artery disease,  a history of
myocardial infarction, and other causes of MR, 190 patients
were included. The aortic valvular pathology included severe
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Arrhythmias
Visually-Guided Balloon Catheter Ablation of Atrial
Fibrillation. Experimental Feasibility and First-in-
Human Multicenter Clinical Outcome
Reddy VY, Neuzil P, Themistoclakis S, et al.
Circulation 2009;120:12–20.
Study Design: What is the efficacy of a balloon-based endo-
scopic laser-ablation system (ELAS) in patients with
symptomatic paroxysmal atrial fibrillation (PAF)?
Methods: After preclinical experiments in 20 dogs demon-
strated that transmural lesions were safely created at the left
atrial-pulmonary vein (LA-PV) junction, the ELAS was
used for pulmonary vein (PV) isolation in 30 patients (mean
age 53 years) with PAF. The size of the laser arc was 90° or
150° and laser applications lasted 60 seconds. All patients
underwent periodic 24-hour Holter and event monitor
recordings during a 12-month follow-up.
Results: Among the 30 patients, 105/116 PVs (91%) were
acutely isolated with the ELAS, requiring a mean of 13.9
energy applications per PV. The mean procedure duration
was ~5.5 hours. Single-procedure efficacy at 12 months was
67% on antiarrhythmic drugs and 60% off drugs. Three
patients (10%) had a complication: ischemic neurologic
deficit, cardiac tamponade, or right phrenic nerve palsy.
Conclusions: A balloon-based ELAS that allows direct visuali-
zation of the LA-PV junction is moderately effective for
eliminating symptomatic PAF.
Results: No in-hospital or 30-day mortality was identified.
Overall incidence of valve-related complications at 30 days
was 3%. In comparing AVR versus AVS groups, those with
AVS were significantly younger and less likely to have had
previous repair of a type A dissection. AV regurgitation was
more common in the AVR (20%) than the AVS (5%, p =
0.005) group. The decision to perform AVR versus AVS was
made intraoperatively in 43% of patients. The AVR group
had a significantly higher portion of patients undergoing
emergent or urgent operative procedures.
Conclusions: Valve-sparing techniques were the most common
approach to root replacement at the 18 sites. However, valve-
sparing root replacement did not translate into any early
demonstrable improvement or detriment of early outcomes.
Perspective: Despite the increasing complexity and time
required to perform a valve-sparing procedure, there was no
difference in early outcomes. I suspect the results are not
applicable to all surgeons, as a valve-sparing root replace-
ment is perhaps best reserved for those who have significant
experience with aortic root surgery. The mechanical AVR or
tissue composite AVR is a standard operative procedure that
may be more easily adopted by those with less experience.
The importance of this study will be when the 3-year dura-
bility is compared. 
Summary written by: Himanshu J. Patel, MD
Congenital Heart Disease
Prevalence and Repair of Intraoperatively
Diagnosed Patent Foramen Ovale and Association
With Perioperative Outcomes and Long-Term
Survival
Krasuski RA, Hart SA, Allen D, et al.
JAMA 2009;302:290–297. 
Study Design: What are the outcomes for surgical repair of
incidentally discovered patent foramen ovale (PFO)?
Methods: Intraoperative transesophageal echos from 13,092
patients undergoing surgery at the Cleveland Clinic (1995-
2006) were reviewed for evidence of PFO. No patients had a
prior diagnosis of PFO or atrial septal defect. Postoperative
outcomes were prospectively collected until discharge. Primary
outcomes were all-cause hospital mortality and stroke.
Secondary outcomes included length of hospital and intensive
care unit stay, and time on cardiopulmonary bypass.
Results: A total of 2,277 (17%) patients were diagnosed with
PFO via intraoperative transesophageal echo. Rates of PFO
diagnosed intraoperatively did not change over time; however,
aortic stenosis, regurgitation, or both. Survival was assessed by
a case-matched comparison of patients with and without MR
at the time of AVR. Patients were matched with respect to
age, gender, and left ventricular ejection fraction.
Results: The predominant valve pathology was aortic stenosis
in 83 patients. The degree of MR was grade 2 in the major-
ity (89%), with grade 4 present in only one. Operative
procedures included bioprosthetic AVR in 137 and mechan-
ical prosthetic AVR in 44. AVR was an isolated procedure
in 139 patients. At discharge, MR was mild or less in 72%.
At last follow-up, the spectrum of MR severity was stable
(mean follow-up 3 years), and no reoperation was identified
for postop MR. Ten-year survival was 42%. Long-term sur-
vival with an age- and gender-matched white population in
Minnesota suggested that long-term survival was signifi-
cantly lower amongst the study group (p < 0.001),
irrespective of the degree of residual postoperative MR.
Conclusions: Moderate functional MR improves in most
patients after AVR. Residual MR did not affect survival
independently of left ventricular function.
Perspective: This study suggests that concomitant mitral
repair for moderate or less MR may not be warranted, as it
may not impact survival in the setting of severe aortic steno-
sis or insufficiency. The presence of moderate to severe
concomitant tricuspid regurgitation should be taken seri-
ously, as it may be appropriate to consider mitral and
tricuspid repair, as the degree of tricuspid regurgitation may
reflect more physiologically substantial MR. But will this
improve long-term symptoms?  
Summary written by: Himanshu J. Patel, MD   
Valve-Sparing and Valve-Replacing Techniques for
Aortic Root Replacement in Patients With Marfan
Syndrome: Analysis of Early Outcome
Volguina IV, Miller DC, LeMaire SA, et al., on behalf of the Aortic Valve
Operative Outcomes in Marfan Patients Study Group.
J Thorac Cardiovasc Surg 2009;137:641–649.
Study Design: Is there a difference in early outcomes in
patients with Marfan syndrome who undergo aortic valve-
sparing or valve-replacing root operative procedures?
Methods: This prospective international registry study identi-
fied outcomes for either aortic valve replacement (AVR) or
aortic valve-sparing (AVS) root resection in patients with
Marfan syndrome. The primary endpoint was a composite
incidence of all valve-related complications. Thirty-day and
in-hospital outcomes were complete in all 151 patients
included, and discharge echocardiograms were available 
for 95%.
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sion to hospital or death occurred in 61 people in the rosigli-
tazone group and 29 in the active control group. Upper and
distal lower limb fracture rates were increased mainly in
women randomly assigned to rosiglitazone. Mean HbA1c
was lower in the rosiglitazone group at 5 years.
Conclusions: Addition of rosiglitazone to glucose-lowering
therapy in people with type 2 diabetes does not increase the
risk of overall cardiovascular morbidity or mortality com-
pared with standard glucose-lowering drugs.
Perspective: Based on this study’s findings and other evidence,
rosiglitazone is not recommended for people with a history of
heart failure or previous problems that might have led to
myocardial dysfunction, and should also be used with caution
in women at high risk of fractures. Given the limitations of
this open-label study and that evidence is insufficient to rule
out a small increased risk of myocardial infarction caused by
rosiglitazone when compared with other glucose-lowering
agents, rosiglitazone should be used with caution and pru-
dence in the management of type 2 diabetes. 
Summary written by: Debabrata Mukherjee, MD
Cardiovascular Evaluation and Management of
Severely Obese Patients Undergoing Surgery: A
Science Advisory From the American Heart
Association
Poirier P, Alpert MA, Fleisher LA, et al.
Circulation 2009;120:86–95.
Perspective: The following are points to remember from this
science advisory: 
1. Prevalence of obesity in the general U.S. population is
increasing rapidly. It is estimated that the number of individu-
als with a body mass index (BMI) greater than 30 kg/m2 has
doubled in the past 20 years, and roughly 25% are now obese.
This increases the frequency of obese patients undergoing sur-
gery, and the need for surgery to address obesity itself. 
2. Obesity increases the risk of comorbid conditions, some
of which increase the risk of cardiovascular disease and risk.
These include hypertension, metabolic syndrome, diabetes,
and atherosclerotic cardiovascular disease. Obesity also
increases the risk of developing heart failure, pulmonary
hypertension, deep vein thrombosis and pulmonary
embolism (PE), and a sedentary lifestyle. 
3. Obesity increases the frequency of symptoms such as
exertional dyspnea and lower extremity edema unrelated to
cardiovascular disease, thereby reducing the specificity of
these findings. 
rates of repair appeared to increase over time. Similar rates of
in-hospital mortality and postoperative stroke between patients
with and without PFO were observed. Among patients with
PFO, surgical closure was performed in 639 (28%), and was
performed more often among younger patients (mean age 61.1
vs. 64.4 years), females (42% vs. 33%), patients undergoing
mitral or tricuspid valve surgery (51% vs. 32%), or patients
with prior history of transient ischemic attack or stroke (16%
vs. 10%). Postoperative stroke was more common among those
with repaired PFO. No survival difference was observed over
mean follow-up of 5.6 years.
Conclusions: Incidental PFOs are common among patients
undergoing cardiothoracic surgery. Surgical closure appears
unrelated to long-term survival and may result in increased
risk of postoperative stroke.
Perspective: These findings suggest that closure of incidental
PFO is not associated with improved outcomes and may be
associated with increased risk of stroke. Routine closure of
PFO found incidentally would not be recommended based on
this study. 
Summary written by: Elizabeth A. Jackson, MD   
General Cardiology
Rosiglitazone Evaluated for Cardiovascular
Outcomes in Oral Agent Combination Therapy for
Type 2 Diabetes (RECORD): A Multicentre,
Randomised, Open-Label Trial 
Home PD, Pocock SJ, Beck-Nielsen H, et al., on behalf of the RECORD
Study Team.
Lancet 2009;373:2125–2135. 
Study Design: What are cardiovascular outcomes with rosigli-
tazone in combination with metformin or sulfonylurea,
compared with metformin and sulfonylurea dual therapy?
Methods: In a multicenter, open-label trial, 4,447 patients with
type 2 diabetes on metformin or sulfonylurea monotherapy
with mean glycated hemoglobin (HbA1c) of 7.9% were ran-
domly assigned to addition of rosiglitazone (n = 2,220) or
combination of metformin and sulfonylurea (active control
group, n = 2,227). The primary endpoint was cardiovascular
hospitalization or cardiovascular death.
Results: A total of 321 people in the rosiglitazone group and
323 in the active control group experienced the primary out-
come during a mean 5.5-year follow-up, meeting the criterion
of noninferiority. Hazard ratio was 0.84 (0.59-1.18) for car-
diovascular death, 1.14 (0.80-1.63) for myocardial infarction,
and 0.72 (0.49-1.06) for stroke. Heart failure causing admis-
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4. As with nonobese patients, the risk of perioperative cardiac
events in obese patients is related to the risk of underlying
heart disease, associated comorbidities, and type of surgery. 
5. Obesity itself has not been associated with increased mor-
tality of noncardiac surgery, but increases the risk of renal
and pulmonary complications of noncardiac surgery and
increases average length of hospital stay. 
6. The authors report the Obesity Surgery Mortality Risk
Score (OS-MRS) for gastric bypass surgery, which includes
these risk factors: BMI ≥50 kg/m2, male gender, hyperten-
sion, PE risk, and age ≥45 years. Patients were identified as
Class A (low risk) if they had 0-1 identified, with overall
mortality of 0.2%; Class B (intermediate risk), having 2-3
comorbidities, with a 1.2% mortality; and Class C (high
risk), having 4-5 comorbidities, with 2.4% mortality. 
7. The authors suggest use of the Revised Cardiac Risk Index
in decision-making regarding further cardiac evaluation prior
to surgery. Patients with no risk factors may not require fur-
ther testing. Those with ≥3 risk factors or known
cardiovascular disease may require further noninvasive testing
prior to surgery, if the results will change management. 
8. As for perioperative management, it is not clear that obe-
sity itself is associated with difficulty intubating the trachea,
or with extubation. Due to an increased incidence of under-
lying sleep apnea, attention to peri- and postoperative
oxygenation is important, and may require use of nasal con-
tinuous positive airway pressure ventilation in patients who
use this at home.
Summary written by: James B. Froehlich, MD
Genetic Variants Associated With Cardiac
Structure and Function: A Meta-Analysis and
Replication of Genome-Wide Association Data
Vasan RS, Glazer NL, Felix JF, et al.
JAMA 2009;302:168–178.
Study Question: Are common variations in the genome associ-
ated with left ventricular (LV) structural abnormalities
assessed by echocardiography?
Methods: Within five community-based cohorts comprising
the EchoGen consortium (stage 1; n = 12,612 individuals of
European ancestry; 55% women, ages 26-95 years; exams
between 1978-2008), association between ~2.5 million sin-
gle-nucleotide polymorphisms (SNPs) and echocardiographic
traits were analyzed. In stage 2, SNPs significantly associated
with traits in stage 1 were tested for association in two other
cohorts (n = 4,094 people of European ancestry). Using a p
value threshold of 5 x 10-7 to indicate genome-wide signifi-
cance, an inverse fixed-effects meta-analysis of genome-wide
association data from each cohort was performed. The pri-
mary echocardiographic measures were LV mass, internal
dimensions, wall thickness, systolic function, aortic root, and
left atrial size. 
Results: In stage 1, 16 genetic loci were associated with five
echocardiographic traits: one each with LV internal dimen-
sions and systolic dysfunction, three each with LV mass and
wall thickness, and eight with aortic root size. In stage 2,
five loci replicated (6q22 locus associated with LV diastolic
dimensions, explaining <1% of trait variance; 5q23, 12p12,
12q14, and 17p13 associated with aortic root size, explain-
ing 1-3% of trait variance).
Conclusions: Five genetic loci harboring common variants
were associated with variation in LV diastolic dimensions
and aortic root size, but such findings explained a very small
proportion of variance.
Perspective: Although the SNPs in this study accounted for
an extremely small percentage of trait variance, these vari-
ants are novel and could provide new insight into the
pathophysiology of some forms of cardiovascular disease, as
well as uncover therapeutic targets. The specific causal vari-
ant associated with these loci and the mechanism by which
cardiovascular structure is affected by the variant will need
to be identified.  
Summary written by: Daniel T. Eitzman, MD
Migraine Headache in Middle Age and Late-Life
Brain Infarcts
Scher AI, Gudmundsson LS, Sigurdsson S, et al.
JAMA 2009;301:2563–2570.
Study Question: Is history of migraine associated with risk of
silent brain infarcts?
Methods: This was a population-based study of 4,689 men
and women (57%) in Reykjavik, Iceland who were exam-
ined, and interviewed about migraine symptoms in midlife
(average age, 51 years). Brain magnetic resonance images
(MRIs) were performed 26 years later. Participants reporting
headaches once or more per month were classified as having
migraine without aura, migraine with aura, or nonmigraine.
A comprehensive cardiovascular risk assessment was per-
formed at both exams. 
Results: A majority (69%) did not have headaches more than
once a month. Infarct-like lesions were present in 39.3% of
men and 24.6% of women. Those with midlife migraine
with aura (n = 361) had an increased risk of late-life infarct-
like lesions, mainly explained by an increased prevalence of
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Perspective: This analysis suggests that in patients with MI
complicated by heart failure, systolic dysfunction, or both, the
risk of GI bleeding is related to clinical risk factors including
age, nonwhite race, and history of alcohol abuse. Moreover, in
this population, use of dual antiplatelet therapy represents a
very important long-term risk factor for GI bleeding. Thus,
increased vigilance in post-MI patients with multiple risk fac-
tors for GI bleeding is needed.  
Summary written by: Debabrata Mukherjee, MD   
Interventional Cardiology
Stent Placement in Patients With Atherosclerotic
Renal Artery Stenosis and Impaired Renal Function:
A Randomized Trial
Bax L, Woittiez AJ, Kouwenberg HJ, et al.
Ann Intern Med 2009;150:840–848.
Study Question: What is the efficacy and safety of stent place-
ment in patients with atherosclerotic renal artery stenosis
(ARAS) and impaired renal function?
Methods: This randomized clinical trial, conducted in 10
European medical centers, included 140 patients with creati-
nine clearance <80 ml/min per 1.73 m2 and ARAS of ≥50%.
Modalities were stent placement and medical treatment (64
patients) or medical treatment only (76 patients). Medical
treatment consisted of antihypertensives, a statin, and aspirin.
The primary endpoint was ≥20% decrease in creatinine clear-
ance.
Results: Forty-six of 64 patients assigned to stent placement
had the procedure. Ten of the 64 patients (16%) in the stent
placement group and 16 patients (22%) in the medication
group reached the primary endpoint (hazard ratio, 0.73
[95% confidence interval, 0.33-1.61]). Serious complications
occurred in the stent group, including two procedure-related
deaths (3%), one late death secondary to an infected
hematoma, and one patient who required dialysis secondary
to cholesterol embolism. 
Conclusions: Stent placement with medical treatment had no
clear effect on progression of impaired renal function, but
led to a small number of significant procedure-related com-
plications.
Perspective: This study is underpowered and the findings are
compatible with both efficacy and harm and are, therefore,
inconclusive. A considerable number of stent-related compli-
cations also occurred. This and other findings currently favor
a conservative therapeutic approach to patients with ARAS,
focused on cardiovascular risk factor management. The ongo-
cerebellar lesions in women with migraines. Infarcts were
present in 23.0% of women with migraine with aura com-
pared with 14.5% of women not reporting headaches. No
difference was seen in men (19.3% prevalence of infarcts for
men with migraine with aura vs. 21.3% for men not report-
ing headaches). Migraine without aura and nonmigraines
were not associated with an increased risk in the overall
population or in any gender.
Conclusions: Migraine with aura in midlife was associated
with late-life prevalence of cerebellar infarct-like lesions on
MRI.
Perspective: This interesting study will spawn numerous fur-
ther investigations, although its immediate clinical
implications are limited. It is not clear if these MRI find-
ings have clinical relevance, and it would be premature to
screen patients with migraine for these lesions or to treat
these patients any differently at this time.  
Summary written by: Hitinder S. Gurm, MD 
Gastrointestinal Bleeding in High Risk Survivors of
Myocardial Infarction: The VALIANT Trial
Moukarbel GV, Signorovitch JE, Pfeffer MA, et al.
Eur Heart J 2009;Jun 25:[Epub ahead of print].
Study Question: What are the risk factors for gastrointestinal
(GI) bleeding in patients following myocardial infarction
(MI)?
Methods: In the VALIANT trial, 14,703 post-MI patients
with left ventricular dysfunction and/or heart failure were
followed for a median of 24.7 months. In this secondary
analysis, times from baseline to first GI bleeding were iden-
tified from the VALIANT serious adverse event database.
Potential risk factors were explored from medical history,
demographics, clinical profile, and medications at baseline
and during follow-up. Relationship between occurrence of
GI bleeding and subsequent mortality was also explored.
Results: During follow-up, 98 (0.7%) patients had a serious
GI bleeding event. These patients were older, had more
comorbidities, were more likely to be taking additional
antiplatelet drugs, and had worse left ventricular systolic and
renal function. The Kaplan–Meier estimated rate of GI
bleeding at 6 months was 0.37% (95% confidence interval
[CI], 0.27-0.47). In a multivariable Cox model, dual
antiplatelet therapy was the most powerful predictor of GI
bleeding. GI bleeding was associated with increased risk of
death (adjusted hazard ratio, 2.54; 95% CI, 1.66-3.89). 
Conclusions: Following MI, clinical characteristics can identify
patients with increased risk of GI bleeding.
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ing CORAL study may provide additional insight on the
incremental value of stent revascularization for the treatment
of ARAS.  
Summary written by: Debabrata Mukherjee, MD    
Noninvasive Cardiology
Coronary Artery Calcification Screening:
Estimated Radiation Dose and Cancer Risk
Kim KP, Einstein AJ, Berrington de Gonzalez A.
Arch Intern Med 2009;169:1188–1194.
Study Question: What is the estimated organ-specific radia-
tion dose and associated cancer risks from coronary artery
calcification (CAC) screening with multidetector computed
tomography according to patient age, frequency of screen-
ing, and scan protocol?
Methods: Radiation doses to adult patients were calculated
from a range of available protocols using Monte Carlo radi-
ation transport. Radiation risk models, derived from
Japanese atomic bomb survivors and medically exposed
cohorts, were used to estimate the excess lifetime risk of
radiation-induced cancer.
Results: The radiation dose from a CAC CT scan varied
more than 10-fold (effective dose range, 0.8-10.5 mSv)
depending on the protocol. In general, higher radiation
doses were associated with higher X-ray tube current,
higher tube potential, spiral scanning with low pitch, and
retrospective gating. The wide dose variation also resulted
in wide variation in estimated radiation-induced cancer
risk. For the median dose of 2.3 mSv, one screening at the
age of 40 was estimated to result in a lifetime excess cancer
risk of 9 and 28 cancers per 100,000 persons for men and
women, respectively. Assuming screening every 5 years
from the age of 45-75 for men and 55-75 for women, the
estimated excess lifetime cancer risk was 42 cases per
100,000 men and 62 cases per 100,000 women.
Conclusions: These radiation risk estimates can be compared
with potential benefits from screening, when estimates are
available. Doses and therefore risks can be minimized by use
of optimized protocols.
Perspective: Physicians referring patients for CAC scores
should be aware of the variation of radiation exposure
(median 2.3 mSv) at various testing centers, and centers
should modify protocols to limit radiation. About 5,600
individuals undergoing a one-time CAC screen are esti-
mated to develop a radiation-induced cancer. Some
advocate repeating the CAC score within a few years to
assess the effect of therapy. This as well as the ‘every five-
year’ strategy do not consider cancer mortality, and decrease
in quality of life and costs of cancer.  
Summary written by: Melvyn Rubenfire, MD 
Risk Score for Predicting Outcome in Patients
With Asymptomatic Aortic Stenosis
Monin JL, Lancellotti P, Monchi M, et al.
Circulation 2009;120:69–75.
Study Question: What are the predictors of risk for the devel-
opment of symptoms or adverse events in asymptomatic
patients with severe aortic stenosis?
Methods: Asymptomatic patients with moderate to severe
aortic stenosis were followed prospectively for 24 months at
a single center in France. The predefined endpoints were
death, or aortic valve replacement necessitated by symptoms
or positive stress test within 24 months. The authors identi-
fied variables independently associated with outcome and
created a risk score, which was validated in an independent
cohort of 107 patients from Belgium.
Results: Follow-up data were available for 104 patients.
Factors associated with endpoints were female sex, peak
aortic jet velocity, and B-type natriuretic peptide (BNP) at
baseline. Risk score was = [peak velocity (m/s) x 2] + (nat-
ural logarithm of BNP x 1.5) + 1.5 (if female). After 20
months, event-free survival, stratified by quartile of risk
score, was 80% for patients within the first quartile and 7%
in the fourth quartile. Area under the receiver operating
characteristic curve for this risk score was 0.90 and 0.80 in
the development and validation cohort, respectively.
Conclusions: Should further validation be achieved, the
derived risk score may be useful in predicting outcome for
patients with asymptomatic aortic analysis in order to select
those who may benefit from early surgery.
Perspective: Timing of valvular surgery remains one of the
more challenging clinical questions. This study reported a
simple and logical risk score, which may identify patients
who, though asymptomatic, face an increased risk of death
while waiting for aortic valve surgery, or the development of
symptoms in the short-term, indicating the need for aortic
valve surgery. If these data are validated, high aortic jet
velocity—despite a lack of symptoms—may indicate early
intervention to replace the aortic valve. Such objective data
would be a welcome addition to the clinician’s decision-
making armamentarium.  
Summary written by: James B. Froehlich, MD
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Prevention/Vascular
Lipoprotein(a) Concentration and the Risk of
Coronary Heart Disease, Stroke, and Nonvascular
Mortality
The Emerging Risk Factors Collaboration.
JAMA 2009;302:412–423.
Study Question: What is the relationship between lipoprotein(a)
[Lp(a)] concentration with risk of major vascular and nonvas-
cular outcomes?
Methods: Long-term prospective studies that recorded Lp(a)
concentration and subsequent major vascular morbidity
and/or cause-specific mortality published between January
1970 and March 2009 were identified through manual and
electronic searches of databases, and discussion with collabo-
rators. Within-study regression analyses were adjusted for
within-person variation and combined using meta-analysis.
Analyses excluded participants with known pre-existing
coronary heart disease (CHD) or stroke at baseline.
Results: Individual records were provided for each of 126,634
participants in 36 prospective studies. Mean age at entry of
participants was 57 years and 48% were women; 47% were
European and 50% were North American. The overall
median of Lp(a) at baseline was 12.6 mg/dl and were 12%
higher in women, 11% lower in diabetics, and twofold
higher Lp(a) in blacks than whites. During 1.3 million per-
son-years of follow-up, 22,076 first ever fatal or nonfatal
vascular disease outcomes or nonvascular deaths were
recorded, including 9,336 CHD outcomes, 1,903 ischemic
strokes, 338 hemorrhagic strokes, 751 unclassified strokes,
1,091 other vascular deaths, 8,114 nonvascular deaths, and
242 deaths of unknown cause. Lp(a) concentration was
weakly correlated with several conventional vascular risk fac-
tors, and it was highly consistent within individuals over
several years. Associations of Lp(a) with CHD risk were
broadly continuous in shape.
Conclusions: Under a wide range of circumstances, there are
continuous, independent, and modest associations of Lp(a)
concentration with risk of CHD and stroke that appear exclu-
sive to vascular outcome.
Perspective: The risk attributable to Lp(a) is only about one-
quarter as strong overall as non–high-density lipoprotein
(HDL) cholesterol. But as the authors point out, the contri-
bution of Lp(a) may become proportionally more important
to CHD at very high concentrations, owing to its potentially
curvilinear risk relationship. Translating the findings to a
level of Lp(a) at which the risk is significant, the 16%
increase in risk for a 3.5-fold higher than the median level of
Lp(a) point is in the order of 40 mg/dl, which is about the
90th percentile.  
Summary written by: Melvyn Rubenfire, MD
Diet and Lifestyle Risk Factors Associated With
Incident Hypertension in Women
Forman JP, Stampfer MJ, Curhan GC.
JAMA 2009;302:401–411.
Study Question: Are diet and lifestyle factors associated with
hypertension in women?
Methods: Data on women from the second Nurses’ Health
Study were used for this analysis. Subjects ages 27-44, who
did not have hypertension, cardiovascular disease, or cancers
at baseline (1991) were followed through 2005. Women
also had to have reported a normal blood pressure at base-
line, defined as systolic blood pressure ≤120 mm Hg and
diastolic ≤80 mm Hg. Six modifiable risk factors for hyper-
tension were examined in combination of low-risk factors,
three factors (normal body mass index [BMI ≤25], daily
vigorous exercise, and DASH-style diet), four factors (three
low-risk factors plus modest alcohol intake), five factors
(four low-risk factors plus avoidance of non-narcotic anal-
gesics), and six factors (five low-risk factors plus folic acid
supplementation of 400 μg/d). 
Results: A total of 83,882 participants were included, with
12,319 incident cases of hypertension reported during the
14 years of follow-up. Each of the lifestyle factors examined
was independently associated with the risk for developing
hypertension, after adjustment for potential confounders
such as age, race, and smoking status. Women with all six
low-risk lifestyle factors (0.3%) were at low risk for incident
hypertension. The hypothetical population-attributable risk
(PAR) was 78% for women who lacked these low-risk fac-
tors. For women with less than six low-risk factors, the
PAR was 72% for five low-risk factors; 58% for four low-
risk factors; and 53% for three low-risk factors. BMI alone
was the most powerful predictor of hypertension. An esti-
mated 40% of new hypertension cases could be attributed to
being overweight or obese (BMI ≥25) and 50% of new cases
could be attributed to a BMI of ≥23. 
Conclusions: Adherence to a healthy diet and other lifestyle
factors, including a healthy BMI, is associated with a lower
incidence of hypertension.
Perspective: These findings suggest that lifestyle can be a criti-
cal area for prevention of hypertension. It is concerning that
so few of the women in this cohort reported these low-risk
lifestyle factors. Clinicians who care for young women may
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assist in prevention of hypertension by counseling their
patients regarding lifestyle factors.  
Summary written by: Elizabeth A. Jackson, MD 
The Benefits of Statins in People Without
Established Cardiovascular Disease but With
Cardiovascular Risk Factors: Meta-Analysis of
Randomised Controlled Trials
Brugts JJ, Yetgin T, Hoeks SE, et al.
Brit Med J 2009;338:b2376.
Study Question: Do statins reduce all-cause mortality and
major coronary and cerebrovascular events in people without
established cardiovascular disease but with cardiovascular risk
factors, and are the effects similar in men and women, in
young and older (>65 years) people, and in people with dia-
betes mellitus?
Methods: A meta-analysis of randomized trials was conducted
using the Cochrane controlled trials registry, EMBASE, and
MEDLINE. Investigators identified studies on the clinical
effects of statins compared with a placebo or control group
and with follow-up of at least 1 year, at least 80% or more
participants without established cardiovascular disease, and
outcome data on mortality and major cardiovascular disease
events.
Results: Ten trials enrolled a total of 70,388 people; 34%
were women and 23% had diabetes mellitus. The mean age
was 63 years and mean follow-up was 4.1 years. The mean
baseline low-density lipoprotein cholesterol (LDL-C) level
was 140 mg/dl. The mean reduction in levels of total choles-
terol was 17.1%, LDL-C 25.6%, and triglyceride 9.3%;
high-density lipoprotein cholesterol increased by a mean of
3.3%. Treatment with statins significantly reduced the risk
of all-cause mortality, and major coronary and  cerebrovascu-
lar events. No evidence of an increased risk of cancer was
observed. There was no significant heterogeneity of the
treatment effect in clinical subgroups by gender, age, and
diabetes.
Conclusions: In patients without established cardiovascular dis-
ease but with cardiovascular risk factors, statin use was
associated with significantly improved survival and large
reductions in the risk of major cardiovascular events.
Perspective: The studies reflect a fairly low-risk group, consid-
ering the LDL-C of 140 mg/dl at baseline and the 1.1%
annual coronary event rate and 1.4% annual mortality in the
placebo groups. Statins reduced cardiovascular and all-cause
mortality in persons at risk and without clinical vascular dis-
ease. Follow-up is too short to draw conclusions about statin
therapy and incident cancer.  
Summary written by: Melvyn Rubenfire, MD 
Adiponectin Levels and Risk of Type 2 Diabetes: A
Systematic Review and Meta-Analysis
Li S, Shin JJ, Ding EL, van Dam RM.
JAMA 2009;302:179–188.
Study Question: What is the relationship between plasma
adiponectin levels and risk of developing type 2 diabetes?
Methods: This systematic review and meta-analysis of 13
prospective studies evaluated the association of type 2 dia-
betes risk and plasma adiponectin levels. Plasma
adiponectin level was considered the “exposure” and inci-
dence of type 2 diabetes was the outcome. Least squares
trend estimation was utilized to assess for a dose-response
relationship. Pooled relative risk estimates with 95% confi-
dence limits were calculated. Where possible, other markers
of glycemia and insulin sensitivity were analyzed to assess
for an independent predictive nature of adiponectin levels.
Results: A total of 14,598 participants were included; 2,623
incident cases of type 2 diabetes were identified. High levels
of adiponectin were inversely related to diabetes incidence
across the entire population, as well as within different eth-
nic/race subpopulations. The absolute relative risk difference
in cases per 1,000 person-years per 1-log μg/ml increment of
adiponectin was nearly 31 for Americans with impaired glu-
cose tolerance and 3.9 for elderly Americans. In a subanalysis,
the relationship held after adjustment for confounding mark-
ers of glycemia and insulin sensitivity.
Conclusions: A “dose-dependent” relationship exists between
higher levels of plasma adiponectin levels and a lowered risk
of type 2 diabetes.
Perspective: Adiponectin appears to be a strong and consistent
biochemical predictor of type 2 diabetes. Given our current
understanding of the associated biochemical pathways, thera-
pies which increase adiponectin, including lifestyle and
pharmacologic strategies, offer clinical promise.  
Summary written by: Kim A. Eagle, MD 
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